NCT00031733View on ClinicalTrials.gov

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

December 31, 2004

Study Completion Date

November 30, 2007

Conditions

Intraocular MelanomaMelanoma (Skin)

Interventions

BIOLOGICAL

MART-1 antigen

BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

recombinant interleukin-12

BIOLOGICAL

sargramostim

BIOLOGICAL

tyrosinase peptide

DRUG

alum adjuvant

PROCEDURE

adjuvant therapy

Trial Locations (1)

90089

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT00031733 - Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma | Biotech Hunter | Biotech Hunter